—
C+
C+ The full Closelooknet — membership. Open the C+ overview

CSL Ltd (CSL.AX) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for CSL.AX, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06

Company snapshot — CSL Ltd

CSL.AX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
CSL Ltd is an Australian biotechnology company that develops and manufactures plasma-derived therapies through its CSL Behring division and produces influenza vaccines through its Seqirus unit. It runs manufacturing and research operations across several countries and lists on the Australian Securities Exchange.
Where it sits in the stack
CSL holds no seat in Rubin or Halo, the diary's AI build-out indices, so it sits outside that stack entirely. It belongs instead to the wider healthcare and biotechnology part of our universe, which the diary follows without scoring for AI exposure.
Who it is priced against
Closelooknet's peer group data carries no entry for CSL. The comparison the wider market draws is with other plasma-therapy and biologics makers, such as Grifols.
Why Closelooknet tracks it
CSL carries no index seat and no Closelooknet score in either module, and the diary has not yet quoted it in an edition.
What the diary watches
The diary watches whether CSL's share price, which has run well ahead of its shorter and longer moving averages, holds that pace or pulls back toward levels seen earlier in its range.

CSL Ltd (CSL.AX) trades on the AU exchange in Australia.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 2.29%, semi-annual · last 2.28 AUD on 2026-09-09

Dividends and capital return

What CSL.AX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 4.09 AUD per share · a 2.29% yield on the 2026-10-06 close 2 distributions, paid twice a year 2026-10-06
  • Change on the year −9.6% against the prior twelve months prior twelve months 4.52 AUD per share
  • Last distribution 2.28 AUD per share as the price series records it, within days of the ex-date 2026-09-09
  • By calendar year 2025: 4.52 AUD (partial) · 2026: 4.09 AUD to date first distribution recorded in the three-year window: 2025-03-10

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is CSL Ltd (CSL.AX)?

CSL Ltd trades as CSL.AX on the AU exchange (Australia) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is CSL.AX in a Closelooknet index?

Not currently — CSL Ltd is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does CSL.AX trade against its moving averages?

Bullish stack, 200-day still turning: Trades +10.2% vs the 50-day and +25.6% vs the 200-day average, 18.6% below the 52-week high and +98.5% off the 52-week low; a golden cross printed 18 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

What does CSL Ltd do?

CSL Ltd is an Australian biotechnology company that develops and manufactures plasma-derived therapies through its CSL Behring division and produces influenza vaccines through its Seqirus unit. It runs manufacturing and research operations across several countries and lists on the Australian Securities Exchange. Closelooknet's peer group data carries no entry for CSL. The comparison the wider market draws is with other plasma-therapy and biologics makers, such as Grifols.

Where does CSL Ltd sit in the AI build-out?

CSL holds no seat in Rubin or Halo, the diary's AI build-out indices, so it sits outside that stack entirely. It belongs instead to the wider healthcare and biotechnology part of our universe, which the diary follows without scoring for AI exposure. CSL carries no index seat and no Closelooknet score in either module, and the diary has not yet quoted it in an edition.

Does CSL Ltd pay a dividend?

CSL Ltd has paid 4.09 AUD per share over the last twelve months, paid twice a year, a trailing yield of 2.29% on the 2026-10-06 close; the last distribution recorded in the price series was 2.28 AUD on 2026-09-09. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for CSL.AX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.